Other languages NanoViricides, Inc.

Equities

NNVC

US6300873022

Market Closed - Nyse Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
2.03 ^USD	+20.83%		+79.65%	+99.02%

08/05	NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	CI
06/05	NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	08/05
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	06/05
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	30/04
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	15/02
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	01/02
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	29/01
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	28/11
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	14/11
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	14/23/14
Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2	21/23/21
Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides	11/23/11
Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well	06/23/06
Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun	29/23/29
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	16/23/16
NanoViricides Files $150 Million Mixed Shelf	08/23/08
NanoViricides, Inc. Enters into License Agreement with Karveer Meditech Private Limited	01/23/01
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	15/23/15
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	15/22/15
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	14/22/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NanoViricides, Inc.

Equities

NNVC

US6300873022

Other languages

Filters